Amgen (CHIX:AMGD) Cash Flow from Others: €-668 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMGD Amgen Inc CHIX:AMGD
80 GF Score
Price €285.00
GF Value €266.26
! 8 Warning Signs
View Full Analysis

What is Amgen Cash Flow from Others?

Amgen CHIX:AMGD 80 Cash Flow from Others is €-668 Mil as of Jun. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 80/100 and a GF Value™ of €266.26. The stock has 8 warning signs investors should review.

Amgen's cash flow from others for the three months ended in Jun. 2026 was €202 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2026 was €-668 Mil.

Amgen Cash Flow from Others Related Terms

Amgen Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Amgen's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cash Flow from Others Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,129.26 1,210.21 -1,689.11 -17.19 -1,635.41

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 460.38 -1,703.15 766.89 65.74 202.24
CHIX:AMGD
80GF Score
Amgen Inc CHIX:AMGD
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-668 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of €-668 Mil mean?
Amgen (CHIX:AMGD) has a Cash Flow from Others of €-668 Mil as of Jun. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Amgen and its competitors.
Is Amgen's Cash Flow from Others too high?
Amgen's current Cash Flow from Others is €-668 Mil. Overall, Amgen has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cash Flow from Others compare to GILD and PFE?
Amgen's Cash Flow from Others of €-668 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Drug Manufacturers company?
A good Cash Flow from Others depends on the Drug Manufacturers industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Amgen and its competitors. Amgen's current Cash Flow from Others is €-668 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (CHIX:AMGD) has a current Cash Flow from Others of €-668 Mil. The stock's GF Value™ is €266.26, compared to a current price of €285.00 — trading 7% above its estimated fair value. The current Cash Flow from Others is €-668 Mil. Amgen's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Cash Flow from Others is €-668 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €285.00 is trading 7% above its estimated GF Value™ of €266.26.

Key valuation signals for CHIX:AMGD:

  • Cash Flow from Others: €-668 Mil
  • GF Value™: €266.26 vs. price of €285.00 (7% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
80GF Score

Get the complete analysis for CHIX:AMGD

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€266.26
GF Value